PTEN underexpression
|
CLL
|
PTEN underexpression
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
PTEN underexpression
|
Hormone Receptor Positive Breast Cancer
|
PTEN underexpression
|
Hormone Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
|
tamoxifen Resistant: C3 – Early Trials
|
PTEN underexpression
|
Pancreatic Cancer
|
PTEN underexpression
|
Pancreatic Cancer
|
trametinib + dabrafenib Resistant: C4 – Case Studies
|
trametinib + dabrafenib Resistant: C4 – Case Studies
|
PTEN underexpression
|
CML
|
PTEN underexpression
|
CML
|
imatinib Sensitive: D – Preclinical
|
imatinib Sensitive: D – Preclinical
|
PTEN underexpression
|
Breast Cancer
|
PTEN underexpression
|
Breast Cancer
|
AZD1775 Sensitive: D – Preclinical
|
AZD1775 Sensitive: D – Preclinical
|
PTEN underexpression
|
Prostate Cancer
|
PTEN underexpression
|
Prostate Cancer
|
copanlisib + darolutamide Sensitive: D – Preclinical
|
copanlisib + darolutamide Sensitive: D – Preclinical
|